209 related articles for article (PubMed ID: 26669426)
1. The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice.
Brunn ND; Mauze S; Gu D; Wiswell D; Ueda R; Hodges D; Beebe AM; Zhang S; Escandón E
J Pharmacol Exp Ther; 2016 Mar; 356(3):574-86. PubMed ID: 26669426
[TBL] [Abstract][Full Text] [Related]
2. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
3. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
4. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
6. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.
Murphy JT; Burey AP; Beebe AM; Gu D; Presta LG; Merghoub T; Wolchok JD
Blood; 2014 Apr; 123(14):2172-80. PubMed ID: 24558202
[TBL] [Abstract][Full Text] [Related]
7. Rational design of anti-GITR-based combination immunotherapy.
Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
[TBL] [Abstract][Full Text] [Related]
8. Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
Sukumar S; Wilson DC; Yu Y; Wong J; Naravula S; Ermakov G; Riener R; Bhagwat B; Necheva AS; Grein J; Churakova T; Mangadu R; Georgiev P; Manfra D; Pinheiro EM; Sriram V; Bailey WJ; Herzyk D; McClanahan TK; Willingham A; Beebe AM; Sadekova S
Cancer Res; 2017 Aug; 77(16):4378-4388. PubMed ID: 28611044
[TBL] [Abstract][Full Text] [Related]
9. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Miyazaki M; Ikeda S; Tsumura H
Oncol Rep; 2015 Oct; 34(4):1995-2001. PubMed ID: 26239052
[TBL] [Abstract][Full Text] [Related]
11. GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells.
Koh CH; Kim IK; Shin KS; Jeon I; Song B; Lee JM; Bae EA; Seo H; Kang TS; Kim BS; Chung Y; Kang CY
Cancer Immunol Res; 2020 May; 8(5):698-709. PubMed ID: 32122993
[TBL] [Abstract][Full Text] [Related]
12. GITR Agonism Enhances Cellular Metabolism to Support CD8
Sabharwal SS; Rosen DB; Grein J; Tedesco D; Joyce-Shaikh B; Ueda R; Semana M; Bauer M; Bang K; Stevenson C; Cua DJ; Zúñiga LA
Cancer Immunol Res; 2018 Oct; 6(10):1199-1211. PubMed ID: 30154083
[TBL] [Abstract][Full Text] [Related]
13. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
14. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
[TBL] [Abstract][Full Text] [Related]
15. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
17. Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice.
Belmar NA; Chan SW; Fox MI; Samayoa JA; Stickler MM; Tran NN; Akamatsu Y; Hollenbaugh D; Harding FA; Alvarez HM
J Immunol; 2017 Jun; 198(11):4502-4512. PubMed ID: 28446565
[TBL] [Abstract][Full Text] [Related]
18. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
19. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
20. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
